2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2180

Presentation, Diagnosis, and Treatment Of Chronic Recurrent Multifocal Osteomyelitis
Abstract Number: 1016

Presenteeism Predicts Sick Leave Better Than Basdai and/Or BASFI In A Longitudinal Cohort Of Patients With Ankylosing Spondylitis (EASIC)
Abstract Number: 1480

Prevalance Of Rare Variants In Methotrexate Pathway Genes: Implications From The National Heart Lung Blood Institute (NHLBI) Exome Sequencing Project
Abstract Number: 131

Prevalence and Antecedents Of Fibromyalgia In Elderly Women
Abstract Number: 2809

Prevalence and Clinical Presentation Of Lyme Arthritis In a Large Cohort Of Patients With Recent-Onset Arthritis
Abstract Number: 1318

Prevalence and Impact Of Soft Tissue Manifestations In Early Inflammatory Arthritis: Results From The Canadian Early Arthritis Cohort
Abstract Number: 1696

Prevalence and Incidence of Systemic Lupus Erythematosus in a Population-Based Registry of American Indian and Alaska Native People in the United States, 2007-2009
Abstract Number: 1254

Prevalence Of Antinuclear Antibodies In Schoolchildren Across Puberty and Possible Relationship With Musculoskeletal Pain. A Longitudinal Study
Abstract Number: 2437

Prevalence Of Axial Spondyloarthritis In The United States Among Patients With Chronic Back Pain and Other Spondyloarthritis-Related Features
Abstract Number: 1983

Prevalence Of Birefringent Crystals In Three Inflammation-Prone Tissues
Abstract Number: 392

Prevalence Of Cardiovascular Risk Factors and Cardiovascular Disease In Rheumatoid Arthritis Patients Across International Regions: A Comparison Of The Corrona International and Corrona United States Registries
Abstract Number: 2443

Prevalence Of Coronary Heart Disease In Spondyloarthopathies may Be Increased Due To Higher Prevalence Of Risk Factors As Well As The Disease Itself- A Retrospective Analysis At Single VA Medical Center
Abstract Number: 98

Prevalence Of Femoroacetabular Impingement Among Chinese Living In Vancouver, Canada: A Population-Based Study
Abstract Number: 2471

Prevalence Of Inflammatory Back Pain In Psoriatic Arthritis: The Prepare Study
Abstract Number: 2435

Prevalence Of Inflammatory Lesions MRI-Spine In Patients With Chronic Back Pain Of ≤2 Years Duration Included In The SPACE-Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].